Genitourinary Cancer News

For pediatric cancer survivors, the disease and its treatments place them at risk for subsequent health complications, many of which are endocrine related.

Myalgia and arthralgia related to checkpoint-inhibitor treatment for genitourinary cancer can vary in timing, severity and treatment, and a multidisciplinary approach, including input from a rheumatologist, is critical for managing these events, according to data published in Clinical Genitourinary Cancer.

HemOnc Today is pleased to announce plans for a 3-day CME meeting designed to offer expert perspectives on advances in cancer treatment.

Monitoring tumor markers may be an effective relapse-detection strategy for certain children with nongerminomatous malignant germ cell tumors, according to a study published in Journal of Clinical Oncology.

In this guest commentary from the steering committee for the Collaborative Group of the Americas on Inherited Gastrointestinal Cancers (CGA-IGC), Michael Hall, MD, of Fox Chase Cancer Center, Matthew Yurgelun, MD, of the Dana-Farber Cancer Institute, Swati Patel, MD, of the University of Colorado, and Heather Hampel, MS, LGC, of the Ohio State University Medical Center, address the need for greater physician awareness amidst the growing uptake of direct-to-consumer genetic testing that may or may not indicate an increased risk for certain gastrointestinal and other cancers. CGA-IGC is a clinical research group focused on hereditary GI cancers. It supports greater access to genetic testing, but with guidelines and research necessary to comprehend the downstream impact.

SAN FRANCISCO — Tivozanib induced higher 2-year PFS and objective response rates than sorafenib among patients with refractory metastatic renal cell carcinoma, according to results from the phase 3 randomized, multicenter TIVO-3 study presented at Genitourinary Cancers Symposium.

Excess body weight is responsible for at least one in 17 new cancers in each state in the U.S., according to a study published in JAMA Oncology.

SAN FRANCISCO — The OS and objective response rate benefits of nivolumab and ipilimumab compared with sunitinib persisted long-term among patients with advanced renal cell carcinoma, according to 30-month follow-up of the phase 3 CheckMate 214 trial presented at Genitourinary Cancers Symposium.

Rivaroxaban led to substantially lower incidence of venous thromboembolism and death of VTE among ambulatory patients with cancer death during the treatment intervention, according to results of the phase 3b randomized trial CASSINI published in The New England Journal of Medicine.

SAN FRANCISCO — The combination of atezolizumab and bevacizumab demonstrated antitumor activity and appeared safe in patients with non-clear cell renal cell carcinoma, according to results of a phase 2 study presented at Genitourinary Cancers Symposium.